Olema Pharmaceuticals develops experimental oral drugs for breast cancer, based in San Francisco. OLMA reports earnings on Mon, Nov 9, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (4 buy, 0 hold, 0 sell).
Prices, price targets and earnings estimates for OLMA are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
No whale options trades in OLMA in the last 90 days.
Total alerts
0
Bullish
0
0%
Bearish
0
0%
Date span
—
Loading…
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether OLMA is in one of them and how their past OLMA trades turned out.
Olema Pharmaceuticals is a drug developer based in San Francisco, California. It is developing oral medicines for breast cancer, led by palazestrant, an experimental drug that blocks the estrogen receptor and breaks it down. The company is also developing OP3136, a treatment that targets the KAT6 protein. If approved, these drugs would be prescribed to women with breast cancer. None of its products are approved for sale yet, so it has no product sales.
